amount of compound available to exert an effect (*e.g.*, fraction unbound in plasma, half-life of the compound in circulation, etc.) can be affected by small changes between two similar compounds. Thus, compounds similar to 6-(6-{[(1R,2R,3S,5S)-2-fluoro-8-azabicyclo[3.2.1]octan-3-yl](methyl)amino}pyridazin-3-yl)-2-methyl-1,3-benzoxazol-5-ol, but with improved metabolic profiles are useful in developing therapies for neurodegenerative diseases, such as Huntington's Disease.

[0008] In one aspect, described herein is a compound of structure B, or a pharmaceutically acceptable salt or stereoisomer thereof:



Structure B.

[0009] In some aspects, the compound of structure B is 6-(6-(((1*R*,2*R*,3*S*,5*S*)-2-Fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazine-3-yl)-2-methylbenzo[*d*]oxazol-5-ol.

[0010] Also provided herein are pharmaceutical compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient or carrier.

[0011] Also provided herein are methods of modulating splicing comprising contacting a compound disclosed herein to cells, wherein the compound modulates splicing at a splice site sequence of a pre-mRNA that encodes an mRNA, wherein the mRNA encodes a target protein or a functional RNA.

[0012] Also provided herein are methods of treating a disease or condition comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt or stereoisomer thereof, to a subject in need thereof.

[0013] Also provided herein are uses of a compound disclosed herein, or a pharmaceutically acceptable salt or stereoisomer thereof, in the manufacture of a medicament for the treatment of a condition or disease.

[0013a] In one aspect, there is provided the compound as described herein or a pharmaceutically acceptable salt or stereoisomer thereof, for use as a medicament for the treatment of a condition or disease.

[0013b] In another aspect, the present disclosure provides the pharmaceutical composition described herein for use as a medicament for the treatment of a condition or disease.

INCORPORATION BY REFERENCE

[0014] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

DETAILED DESCRIPTION

[0015] Certain specific details of this description are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the

CLAIMS

What is claimed is:

1. A compound of structure B, or a pharmaceutically acceptable salt or a stereoisomer thereof:



Structure B.

2. The compound of claim 1, wherein the compound is



(Structure B) or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein the compound is



(Structure A) or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, wherein the compound is



(Structure B).

5. The compound of claim 1, wherein the compound is



(Structure A).

6. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient or carrier.

7. A pharmaceutical composition comprising the compound of claim 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

8. A pharmaceutical composition comprising the compound of claim 4, and a pharmaceutically acceptable excipient or carrier.
9. A method of modulating splicing comprising administering to cells the compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound modulates splicing at a splice site sequence of a pre-mRNA that encodes an mRNA, wherein the mRNA encodes a target protein or a functional RNA.
10. The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, for use as a medicament for the treatment of a condition or disease.
11. The pharmaceutical composition of any one of claims 6 to 8 for use as a medicament for the treatment of a condition or disease.